Paternity and Testicular Function Among Testicular Cancer Survivors Treated With Two to Four Cycles of Cisplatin-Based Chemotherapy

European Urology

Volumn 58, Issue 1, 2010, Pages 134-141

  Brydøy, Marianne ^a,b   Fosså, Sophie D ^c,d   Klepp, Olbjørn ^e   Bremnes, Roy M ^f,g   Wist, Erik A ^d,h   Wentzel Larsen, Tore ^a   Dahl, Olav ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF TROMSØ   (Norway)

^g UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^h ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Chemotherapy; Fertility; Follicle stimulating hormone; Germ cell cancer; Gonadal function; Paternity; Sperm count; Testicular cancer; Testicular function

Indexed keywords

ANDROGEN; BLEOMYCIN; CISPLATIN; ETOPOSIDE; LUTEINIZING HORMONE; SEX HORMONE; TESTOSTERONE; VINBLASTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER SURVIVOR; CLINICAL EXAMINATION; CONTROLLED STUDY; EJACULATION DISORDER; FOLLOW UP; HEALTH SURVEY; HUMAN; LABORATORY TEST; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIPLE CYCLE TREATMENT; ORCHIECTOMY; PATERNITY; PRIORITY JOURNAL; SELF REPORT; SPERMATOZOON COUNT; TESTIS CANCER; TESTIS FUNCTION; TESTOSTERONE BLOOD LEVEL;

EID: 77952881067     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.03.041     Document Type: Article

References (30)

1. Skakkebæk N.E., Rajpert-De Meyts E., and Main K.M. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum Reprod 16 (2001) 972-978
2. Brydøy M., Fosså S.D., Dahl O., and Bjøro T. Gonadal dysfunction and fertility problems in cancer survivors. Acta Oncol 46 (2007) 480-489
3. Lampe H., Horwich A., Norman A., Nicholls J., and Dearnaley D.P. Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol 15 (1997) 239-245
4. Hansen P.V., Trykker H., Svennekjaer I.L., and Hvolby J. Long-term recovery of spermatogenesis after radiotherapy in patients with testicular cancer. Radiother Oncol 18 (1990) 117-125
5. Huddart R.A., Norman A., Moynihan C., et al. Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer 93 (2005) 200-207
6. Huyghe E., Matsuda T., Daudin M., et al. Fertility after testicular cancer treatments: results of a large multicenter study. Cancer 100 (2004) 732-737
7. Brydøy M., Fosså S.D., Klepp O., et al. Paternity following treatment for testicular cancer. J Natl Cancer Inst 97 (2005) 1580-1588
8. Krege S., Beyer J., Souchon R., et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part I. Eur Urol 53 (2008) 478-496
9. Krege S., Beyer J., Souchon R., et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol 53 (2008) 497-513
10. Saxman S. Doctor ... will I still be able to have children?. J Natl Cancer Inst 97 (2005) 1557-1559
11. World Health Organization. WHO laboratory manual for the examination of human semen and sperm-cervical mucus interaction. 3rd ed. (1992), Cambridge University Press, New York, NY
12. Keel B.A. Within- and between-subject variation in semen parameters in infertile men and normal semen donors. Fertil Steril 85 (2006) 128-134
13. Heidenreich A., Thüer D., and Polyakov S. Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis. Eur Urol 53 (2008) 260-274
14. Jacobsen K.D., Ous S., Wæhre H., et al. Ejaculation in testicular cancer patients after post-chemotherapy retroperitoneal lymph node dissection. Br J Cancer 80 (1999) 249-255
15. Andersson A.M., Petersen J.H., Jørgensen N., Jensen T.K., and Skakkebæk N.E. Serum inhibin B and follicle-stimulating hormone levels as tools in the evaluation of infertile men: significance of adequate reference values from proven fertile men. J Clin Endocrinol Metab 89 (2004) 2873-2879
16. Nieschlag E., Simoni M., Gromoll J., and Weinbauer G.F. Role of FSH in the regulation of spermatogenesis: clinical aspects. Clin Endocrinol 51 (1999) 139-146
17. Fosså S.D., Ous S., Abyholm T., Norman N., and Loeb M. Post-treatment fertility in patients with testicular cancer. ii. influence of cis-platin-based combination chemotherapy and of retroperitoneal surgery on hormone and sperm cell production. Br J Urol 57 (1985) 210-214
18. Hoei-Hansen C.E., Holm M., Rajpert-De M.E., and Skakkebaek N.E. Histological evidence of testicular dysgenesis in contralateral biopsies from 218 patients with testicular germ cell cancer. J Pathol 200 (2003) 370-374
19. Stephenson W.T., Poirier S.M., Rubin L., and Einhorn L.H. Evaluation of reproductive capacity in germ cell tumor patients following treatment with cisplatin, etoposide, and bleomycin. J Clin Oncol 13 (1995) 2278-2280
20. Böhlen D., Burkhard F.C., Mills R., Sonntag R.W., and Studer U.E. Fertility and sexual function following orchiectomy and 2 cycles of chemotherapy for stage I high risk nonseminomatous germ cell cancer. J Urol 165 (2001) 441-444
21. Chevreau C., Mazerolles C., Soulié M., et al. Long-term efficacy of two cycles of BEP regimen in high-risk stage i nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. Eur Urol 46 (2004) 209-215
22. Cullen M.H., Stenning S.P., Parkinson M.C., et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol 14 (1996) 1106-1113
23. Pont J., Albrecht W., Postner G., Sellner F., Angel K., and Holtl W. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 14 (1996) 441-448
24. Aass N., Fosså S.D., Theodorsen L., and Norman N. Prediction of long-term gonadal toxicity after standard treatment for testicular cancer. Eur J Cancer 27 (1991) 1087-1091
25. Palmieri G., Lotrecchiano G., Ricci G., et al. Gonadal function after multimodality treatment in men with testicular germ cell cancer. Eur J Endocrinol 134 (1996) 431-436
26. Pont J., and Albrecht W. Fertility after chemotherapy for testicular germ cell cancer. Fertil Steril 68 (1997) 1-5
27. Gaffan J., Holden L., Newlands E.S., et al. Infertility rates following POMB/ACE chemotherapy for male and female germ cell tumours-a retrospective long-term follow-up study. Br J Cancer 89 (2003) 1849-1854
28. Brennemann W., Stoffel-Wagner B., Helmers A., Mezger J., Jager N., and Klingmuller D. Gonadal function of patients treated with cisplatin based chemotherapy for germ cell cancer. J Urol 158 (1997) 844-850
29. Nord C., Bjøro T., Ellingsen D., et al. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol 44 (2003) 322-328
30. Peckham M.J., Barrett A., McElwain T.J., and Hendry W.F. Combined management of malignant teratoma of the testis. Lancet 2 (1979) 267-270